. 2015 Aug 15;8(8):11905–11912.

Table 2.

Summary ORs and 95% CI of CYP1A1 MspI polymorphism and lung cancer risk

Analysis model	Study groups	N	OR 95% CI (random effect)	OR 95% CI (fixed effect)	P^a
C vs. T	Total	23	1.21 (1.07-1.37)	1.23 (1.15-1.32)	0.000
	Chinese Han	10	1.25 (1.02-1.55)	1.25 (1.12-1.39)	0.000
	Population-based	14	1.32 (1.13-1.53)	1.31 (1.21-1.42)	0.000
	Hospital-based	7	1.10 (0.89-1.34)	1.10 (0.96-1.26)	0.064
CC vs. TT	Total	23	1.42 (1.11-1.80)	1.44 (1.25-1.67)	0.005
	Chinese Han	10	1.55 (1.00-2.38)	1.49 (1.20-1.85)	0.000
	Population-based	14	1.66 (1.23-2.24)	1.62 (1.37-1.92)	0.000
	Hospital-based	7	1.11 (0.73-1.70)	1.13 (0.83-1.52)	0.092
CC + CT vs. TT	Total	23	1.26 (1.06-1.50)	1.31 (1.18-1.45)	0.000
	Chinese Han	10	1.28 (0.97-1.68)	1.29 (1.11-1.51)	0.002
	Population-based	14	1.41 (1.14-1.73)	1.42 (1.26-1.61)	0.001
	Hospital-based	7	1.15 (0.84-1.56)	1.16 (0.95-1.42)	0.044
CC vs. TT + CT	Total	23	1.30 (1.04-1.61)	1.31 (1.16-1.49)	0.000
	Chinese Han	10	1.43 (0.95-2.16)	1.40 (1.15-1.69)	0.000
	Population-based	14	1.43 (1.07-1.92)	1.41 (1.21-1.63)	0.000
	Hospital-based	7	1.09 (0.82-1.44)	1.08 (0.83-1.40)	0.349

P value for heterogeneity.